• BactiQuant issued a correction, reclassifying its warrant issuance disclosure as inside information under MAR, not a company announcement.
• Board decided to grant 1,247,500 warrants to management and employees, covering 3.32% of share capital.
• Exercise price set at DKK 2.19 per warrant, based on the 10-day volume-weighted average market price.
• Vesting runs monthly from Dec. 1, 2026 to Dec. 1, 2029, conditional on continued employment.
• Warrants become exercisable from Jan. 1, 2030 for 60 months; unexercised warrants lapse.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bactiquant A/S published the original content used to generate this news brief on September 23, 2026, and is solely responsible for the information contained therein.